MMP9 and hepatocellular carcinoma: demonstrated that impaired activation of ERK1/2 and p38 by mTOR inhibition is directly involved in decreased MMP2 and MMP9 expression and, therefore, reduced migration and invasion in hepatocellular carcinoma (Lin et al., 2014).